Peptide having cancer selective translocation function and use thereof
AssigneesSnu R&Db Foundation, Nano Intelligent Biomedical Engineering Corporation Co. Ltd.
InventorsYoon Jeong Park, Chong-Pyoung Chung, Jin Sook Suh, Yoon Jung Choi
Life of this patent
Estimating the term…
Abstract
A method of treating breast cancer is described, in which a peptide having cancer selective translocation function-doxoribicin conjugate is administered. The conjugate includes doxorubicin chemically linked to the N-terminus or C-terminus of a VEGF-binding protein transduction domain (VPTD) peptide represented as SEQ ID NO: 1, wherein the VPTD peptide and doxorubicin are linked to each other by a disulfide bond, and wherein the VPTD peptide binds specifically to vascular endothelial growth factor (VEGF) in tumor cells or tumor tissues.
Claims2
A method of treating a breast cancer, said method comprising a step of administering a peptide having cancer selective translocation function-doxorubicin conjugate, which comprises doxorubicin chemically linked to the N-terminus or C-terminus of VEGF-binding protein transduction domain (VPTD) peptide represented as SEQ ID NO:
- 1, wherein the VPTD peptide represented as SEQ ID NO:
- 1 and doxorubicin are linked to each other by a disulfide bond, and wherein the VPTD peptide represented as SEQ ID NO:
- 1 binds specifically to vascular endothelial growth factor (VEGF) in tumor cells or tumor tissues.
Dependencies are inferred from the claim text.